2022
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer J, Landeros-Weisenberger A, Johnson J, Londono Tobon A, Flores J, Nasir M, Couloures K, Sanacora G, Bloch M. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2022, 20: 241-251. PMID: 37153136, PMCID: PMC10153503, DOI: 10.1176/appi.focus.22020004.Peer-Reviewed Original ResearchTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2021
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusion
2019
N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study
Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study. Journal Of Child And Adolescent Psychopharmacology 2019, 30: 32-37. PMID: 31800306, PMCID: PMC7133418, DOI: 10.1089/cap.2019.0041.Peer-Reviewed Original ResearchConceptsCY-BOCS total scoreN-acetylcysteineYale-Brown ObsessiveTotal scorePlacebo groupNAC groupStudy populationBenefit of NACPlacebo-controlled clinical trialSymptom severityEffect of NACMild adverse eventsOCD symptom severityLarger study populationPediatric obsessive-compulsive disorderSmall pilot studyChildren's Yale-Brown ObsessiveStudy medicationAdverse eventsPrimary outcomeGlutamate dysfunctionObsessive-compulsive disorderWeek 12Future trialsNAC treatment
2013
Lessons Learned from Open-label Deep Brain Stimulation for Tourette Syndrome: Eight Cases over 7 Years
Motlagh MG, Smith ME, Landeros-Weisenberger A, Kobets AJ, King RA, Miravite J, de Lotbinière AC, Alterman RL, Mogilner AY, Pourfar MH, Okun MS, Leckman JF. Lessons Learned from Open-label Deep Brain Stimulation for Tourette Syndrome: Eight Cases over 7 Years. Tremor And Other Hyperkinetic Movements 2013, 3: 03. PMID: 24255802, PMCID: PMC3822402, DOI: 10.5334/tohm.126.Peer-Reviewed Original ResearchDeep brain stimulationYale Global Tic Severity ScaleTourette syndromeBrain targetsBrain stimulationMedication-refractory Tourette syndromeHomogenous clinical entityOpen-label experienceRefractory Gilles deSerious adverse eventsSelection of patientsRisk of surgeryMidline thalamic nucleiTic Severity ScalePatient-specific outcomesAdverse eventsClinical improvementPostoperative improvementClinical entityGlobus pallidusDBS patientsThalamic nucleiInclusion criteriaSeverity ScaleClinical experience